注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
MaxCyte Inc(MaxCyte)是一家生命科学公司。该公司专注于推进细胞疗法的发现、开发和商业化。该公司为从事药物发现和开发、生物制造和细胞治疗(包括基因编辑和免疫肿瘤学)的生物制药合作伙伴提供细胞工程平台。MaxCyte已开发并商业化可促进各种细胞的工程化的Flow Electroporation平台。该公司的ExPERT平台基于Flow Electroporation技术,旨在应对不断扩大的细胞治疗市场,并用于整个细胞治疗领域。ExPERT系列产品包括:ATx、STx和GTx三款仪器。MaxCyte还开发了一种基于将mRNA转染到未受刺激的细胞中以开发免疫细胞疗法的治疗平台CARMA。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Richard Huntington Douglas | 69 | 2018 | Independent Non-Executive Chairman of the Board |
William W. Brooke | 67 | 2004 | Independent Non-Executive Director |
Arthur Michael Mandell | 71 | 2006 | Independent Non-Executive Director |
Stanley Charles Erck | 76 | 2005 | Independent Non-Executive Director |
John Joseph Johnston | 65 | 2016 | Independent Non-Executive Director |
Rekha Hemrajani | 55 | 2021 | Independent Non-Executive Director |
Yasir B. Al-Wakeel | 42 | 2021 | Independent Non-Executive Director |
Cenk Sumen | 50 | 2022 | Member of Scientific Advisory Board |
Nako Nakatsuka | - | 2023 | Member of Scientific Advisory Board |
Oliver Rando | - | 2023 | Member of Scientific Advisory Board |
Patrick J. Balthrop | 67 | 2022 | Independent Non-Executive Director |
Marcela V. Maus | 48 | 2023 | Member of Scientific Advisory Board |
Avery Posey | - | 2023 | Member of Scientific Advisory Board |
Maher Masoud | 48 | 2017 | President, CEO & Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核